Últimas noticias sobre Asana (NYSE:ASAN) Bolsa

Asana

Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

ASAN

Asana presentará sus resultados del cuarto trimestre con ingresos al alza y menor pérdida por acción. ¿Cómo reaccionarán sus acciones?

Asana (ASAN) publicará resultados financieros: lo que los inversores deben saber antes del informe

Upgrades

LYFT

Conoce qué acciones recibieron mejoras clave de calificación por analistas de Wall Street y sus nuevos precios objetivo.

Analistas de Wall Street elevan precios objetivos y calificaciones de acciones clave

DLTR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: DLTR, PD, DKS, ASAN y HPE.

5 acciones en el foco este miércoles: DLTR, PD, DKS, ASAN y HPE

Asana Inc

ASANTE Inc

Asante Gold Corp

Asanuma Corp

General

SPNS

Cyprus Life & Health Insurer Universal Life Selects Sapiens To Modernize Its Core Insurance Processes

<a href="https://www.primis.tech/">Primis</a>&nbsp;is owned by Universal McCann and The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>).

Primis Strengthens Digital Advertising Trust With HUMAN's MediaGuard Pre-Bid Filtering Solution

Barclays analyst Betty Jiang upgrades Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) from Equal-Weight to Overweight and raises the price target from $115 to $122.

Barclays Upgrades Expand Energy to Overweight, Raises Price Target to $122

ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity.
"Early use of IL-6 in sepsis and septic shock patients shows promise in prognosticating short-term and mid-term mortality, and in predicting the development of microbiological positive cultures," said Nathan Shapiro, M.D., Vice Chairman of Emergency Medicine Research at Beth Israel Deaconess Medical Center and Professor of Emergency Medicine at Harvard Medical School. "The findings from SYMON-I raise the potential to use IL-6 measured in the emergency department for early prognosis and to guide management in sepsis."
"The 2025 SAEM Annual Meeting provides a timely opportunity to engage with emergency medicine professionals and share important information related to the role of IL-6 as an early biomarker for the inflammatory response and in the management of sepsis patients," said Mark Feinberg, M.D., Chief Medical Advisor at Bluejay Diagnostics and Professor of Medicine at Harvard Medical School. "Enrollment in our SYMON-II validation clinical study is underway, which will help define IL-6 as a prognostic biomarker for mortality and other impactful critical care endpoints."
Details of the presentation:
Title: Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study (SYMON I)
Presenters: John H. Lee, M.D., Ph.D. and Nathan Shapiro, M.D.
Presentation Date: May 14, 2025
About the Symphony IL-6 Test:
The Symphony Test platform is designed to determine patient acuity for triage and monitoring based on the measurement of a specific biomarker. The Symphony IL-6 Test to determine patient acuity for sepsis triage and monitoring ("Symphony IL-6 Test") is currently Bluejay's lead product candidate.

BJDX

Bluejay Diagnostics Announces Acceptance Of Abstract Related To Symphony IL-6 Test For Presentation At SAEM Annual Meeting

Barclays analyst Dan Levy upgrades Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) from Equal-Weight to Overweight and lowers the price target from $110 to $97.

Barclays Upgrades Autoliv to Overweight, Lowers Price Target to $97

As the gold price crossed $3,200 per ounce for the first time, Ghana, a <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">major gold producer</a>, has officially centralized control over its gold exports under a newly established government entity.
Effective immediately, Ghana Gold Board (GoldBod) becomes the sole institution authorized to buy, sell, assay, and export gold from the country's artisanal and small-scale mining sector to curb illegal mining and <a target="_blank" href="https://www.benzinga.com/news/global/25/02/43514005/escalating-tariff-wars-tighter-african-supply-drive-gold-toward-3000-milestone" rel="noreferrer noopener">boost state revenues</a>.
"The Ghana Gold Board aims to regulate the gold industry, stabilize the cedi, and maximize revenue from gold exports. As Africa's leading gold producer, Ghana derives substantial foreign exchange earnings from gold. However, the benefits accrued from this valuable mineral remain minimal, often coming at a steep environmental cost," Finance Minister Cassiel Ato Baah Forson <a target="_blank" href="https://mofep.gov.gh/news-and-events/2025-01-28/finance-minister-inaugurates-technical-committee-to-establish-gold-board" rel="noreferrer noopener">said</a> in the inaugural statement earlier this year.
The government has also mandated that all foreign gold traders exit the local market by April 30, 2025, though they may still apply to buy gold directly from GoldBod under regulated conditions. All licensed buyers must now conduct transactions in Ghanaian cedis at prices based on the Bank of Ghana's reference rate.
By tightening the regulations, Ghana seeks to address the illegal mining issue, locally known as "galamsey." While small-scale mining accounts for 40% of the country's gold output, an estimated 70 to 80% is unlicensed. Illegal mining causes severe environmental damage, including deforestation, water pollution from mercury and heavy metals, and the destruction of cocoa farms, contributing to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37900275/agriculture-commodities-rise-to-9-year-highs-cocoa-prices-skyrocket-chocolate-lover" rel="noreferrer noopener">spiking cocoa prices</a>.
The impact of galamsey on national revenues is substantial. Although Ghana's gold exports surged by 53.2% in 2024 to $11.64 billion, a large portion of gold produced by informal miners evades legal channels, limiting the government's ability to collect taxes and foreign reserves.
Officials believe consolidating trade under GoldBod will increase fiscal transparency and strengthen the cedi.
Gold mining is vital for the country's economy, contributing around 7% of the GDP and more than 1 million jobs. In 2024, production reached an estimated 4.9 million ounces (around 136 metric tons).
By 2026, major projects like Cardinal Resources' Namdini Mine, Newmont's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) Ahafo North, and Azumah Resources' Black Volta Gold Project could collectively add over 846,000 ounces in annual production.
Ghana will host its inaugural Mining in Motion Summit in Accra from June 2 to 4, 2025, to reinforce its leadership in responsible mining.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44773404/newmont-soars-with-a-new-60-price-target-leads-sp500-higher" target="_blank" rel="noreferrer noopener">Newmont Soars With A New $60 Price Target, Leads S&amp;P 500 Higher</a></li>
</ul>
Photo via Shutterstock

Government

Large Cap

Regulations

Commodities

Legal

GLDM

OUNZ

SGOL

Ghana Tightens Control Over Gold Exports As Yellow Metal Prices Surge

Redwire Selected By Thales Alenia Space To Deliver Docking Mechanisms For Lunar I-Hab Module

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $60 price target.

Reiteration

IONS

Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

At least 55% reported revenue growth from continuing operations compared to prior year
908 Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025.
Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional revenue related to the desktop portfolio, that was divested on March 4, 2025, and will be reflected within the results of discontinued operations in the first quarter of 2025.
Cash, cash equivalents, and marketable securities were approximately $124 million (unaudited) at the end of the quarter, with an additional $4.0 million of cash held in escrow related to the divestiture of the desktop product portfolio. This amount does not include approximately $2.5 million of cash outflows related to transaction expenses to be paid in April 2025.
"Having divested our desktop portfolio in Q1, our team is now fully focused on executing our advanced chemical detection strategy, delivering strong revenue growth in the quarter, both domestically and internationally," said Kevin J. Knopp, CEO and Co-founder. "We are on track and remain committed to our goal of reaching Adjusted EBITDA positivity by the fourth quarter 2025."

MASS

908 Devices Expects Q1 Revenue From Cont. Ops. To Be At Least $11.5M Vs $7.4M Last Year, Reflecting Reported Growth Of About 55%

Barclays analyst Dan Levy downgrades General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Overweight to Equal-Weight and lowers the price target from $70 to $40.

Downgrades

Barclays Downgrades General Motors to Equal-Weight, Lowers Price Target to $40

WIIM

MTVA

MetaVia shares are trading higher after the company announced top-line data from its 4-week Phase 1 multiple ascending dose trial of DA-1726.

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $10 price target.

IMUX

HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $10 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Outperform and maintains $305 price target.

Telsey Advisory Group Maintains Outperform on Lowe's Companies, Maintains $305 Price Target

Needham analyst John Todaro maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy and lowers the price target from $11 to $10.

APLD

Needham Maintains Buy on Applied Digital, Lowers Price Target to $10

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) with a Buy and maintains $10 price target.

CANF

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and raises the price target from $49 to $53.

BBIO

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $53

CRGO

Freightos Limited Facilitated Transactions Grew 25% YoY

Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)

RNTX

Rein Therapeutics Publishes Study On Anti-Fibrotic Effects Of LTI-2355 In IPF And COVID-Related Fibrosis

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and lowers the price target from $18 to $14.

Comments

Asana

Noticias

Últimas noticias sobre Asana (NYSE:ASAN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL